Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

NCT05528458 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
59
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Samsung Medical Center